keyword
https://read.qxmd.com/read/38561588/quetiapine-versus-haloperidol-in-the-management-of-hyperactive-delirium-randomized-controlled-trial
#21
JOURNAL ARTICLE
Tamer Zakhary, Islam Ahmed, Ibrahim Luttfi, Mina Montasser
BACKGROUND: In the population of patients in the intensive care unit (ICU), most studies compared the use of atypical antipsychotics, such as quetiapine, with the use of traditional haloperidol in patients with delirium of various forms and etiologies. The role of such agents in patients with hyperactive delirium is not fully understood. This study compares the effectiveness of quetiapine with haloperidol in treating the hyperactive form of delirium in terms of their effects on the Delirium Rating Scale-Revised-98 (DRS-R-98), length of stay in the ICU, and mortality in critically ill patients...
April 1, 2024: Neurocritical Care
https://read.qxmd.com/read/38560509/neuroleptic-malignant-syndrome-after-overdose-of-haloperidol-a-case-report
#22
Nicole Kraaijvanger, Tim Mieloo
INTRODUCTION: The Neuroleptic Malignant Syndrome (NMS), alternatively referred to as the Antipsychotic Malignant Syndrome, is a potentially fatal condition that is infrequently observed and is linked to the administration of antipsychotic medications. This syndrome is characterized by a disturbance in consciousness, autonomic instability manifesting as hyperthermia, and muscular rigidity. The onset of this syndrome is typically within the initial month of treatment or following an escalation in the dosage of an antipsychotic medication...
June 2024: Toxicology Reports
https://read.qxmd.com/read/38559131/neuronal-alterations-in-akt-isotype-expression-in-schizophrenia
#23
Robert McCullumsmith, Ali Imami, Hunter Eby, Abdul-Rizaq Hamoud, William Ryan, Smita Sahay, Taylen Arvay, Sinead O'Donovan, Sophie Asah, Hasti Golchin, Alex Joyce, Consuelo Walss-Bass, Elizabeth Shedroff, Emily Devine
Schizophrenia is characterized by substantial alterations in brain function, and previous studies suggest insulin signaling pathways, particularly involving AKT, are implicated in the pathophysiology of the disorder. This study demonstrates elevated mRNA expression of AKT1-3 in neurons from schizophrenia subjects, contrary to unchanged or diminished total AKT protein expression reported in previous postmortem studies, suggesting a potential decoupling of transcript and protein levels. Sex-specific differential AKT activity was observed, indicating divergent roles in males and females with schizophrenia...
March 13, 2024: Research Square
https://read.qxmd.com/read/38555909/impact-of-the-early-covid-19-pandemic-on-adult-mental-health-related-dispensed-medications-hospitalizations-and-specialist-outpatient-visits-in-norway-and-sweden-interrupted-time-series-analysis
#24
JOURNAL ARTICLE
David Moreno-Martos, Jing Zhao, Huiqi Li, Fredrik Nyberg, Ludvig Daae Bjørndal, Mohammadhossein Hajiebrahimi, Björn Wettermark, Mia Aakjær, Morten Andersen, Maurizio Sessa, Angela Lupattelli, Hedvig Nordeng, Daniel R Morales
AIMS: Norway and Sweden had different early pandemic responses that may have impacted mental health management. The aim was to assess the impact of the early COVID-19 pandemic on mental health-related care. METHODS: We used national registries in Norway and Sweden (1 January 2018-31 December 2020) to define 2 cohorts: (i) general adult population; and (ii) mental health adult population. Interrupted times series regression analyses evaluated step and slope changes compared to prepandemic levels for monthly rates of medications (antidepressants, antipsychotics, anxiolytics, hypnotics/sedatives, lithium, opioid analgesics, psychostimulants), hospitalizations (for anxiety, bipolar, depressive/mood, eating and schizophrenia/delusional disorders) and specialist outpatient visits...
March 31, 2024: British Journal of Clinical Pharmacology
https://read.qxmd.com/read/38549678/probes-for-the-heterogeneity-of-muscimol-binding-sites-in-rat-brain
#25
JOURNAL ARTICLE
Veronika Müller, Margot Ernst, Aygul Baykuchkarova, Filip Koniuszewski, Konstantina Bampali, Thomas Seidel, Petra Scholze
Introduction: The plant-based alkaloid muscimol is a potent agonist of inhibitory GABAA -neurotransmitter receptors. GABAA receptors are a heterogeneous family of pentameric complexes, with 5 out of 19 subunits assembling around the central anion pore. Muscimol is considered to bind to all receptor subtypes at the orthosteric drug binding site at the β+/α- interface. Recently, we observed that the antipsychotic drugs clozapine (CLZ), loxapine (LOX) and chlorpromazine (CPZ) although exerting functional inhibition on multiple GABAA receptor subtypes showed diverging results in displacing 3H-muscimol...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38540209/impact-of-pharmacogenetic-testing-on-clozapine-treatment-efficacy-in-patients-with-treatment-resistant-schizophrenia
#26
JOURNAL ARTICLE
Estela Sangüesa, Emilio Fernández-Egea, Julia Concha, Cristina B García, María Pilar Ribate
Managing schizophrenia with clozapine poses a significant challenge due to prevalent therapeutic failures. The increasing interest in personalized medicine underscores the importance of integrating pharmacogenetic information for effective pharmacotherapeutic monitoring in patients. The objective of this study was to explore the correlation between DRD2 , HTR2A , SLC6A4 , CYP1A2 , and ABCB1 polymorphisms and clozapine response in 100 patients with Treatment-Resistant Schizophrenia. Different scales such as the Positive and Negative Syndrome Scale (PANSS), the Warwick-Edinburgh Mental Wellbeing Scale (SWEMWBS), the Global Assessment of Functioning Scale (GAF), the Brief Negative Symptom Scale (BNSS), and pharmacokinetic parameters were used to analyse the efficacy of the treatment...
March 7, 2024: Biomedicines
https://read.qxmd.com/read/38540107/the-implications-of-cytochrome-p450-2d6-cyp2d6-polymorphism-in-the-therapeutic-response-of-atypical-antipsychotics-in-adolescents-with-psychosis-a-prospective-study
#27
JOURNAL ARTICLE
Adriana Cojocaru, Adina Braha, Roxana Jeleriu, Nicoleta Ioana Andreescu, Maria Puiu, Luminita Ageu, Roxana Folescu, Carmen Lacramioara Zamfir, Laura Alexandra Nussbaum
BACKGROUND: The plasma level of antipsychotics and their metabolites depends on the activity of the cytochrome P450 (CYP) system in the liver. This research aims to test the individual response variability to atypical antipsychotic drugs, depending on the activity of the CYP2D6 enzyme. METHODS: In a prospective, noninterventional study, we included 56 adolescents, 51.79% male, diagnosed with schizophrenia. The patients underwent DNA sampling for genotyping SNP by RT-PCR and CYP* allelic variants using Applied Bio-systems™ TaqMan® Assays Foster City, CA, USA)...
February 22, 2024: Biomedicines
https://read.qxmd.com/read/38536473/interaction-between-baseline-bmi-and-baseline-disease-severity-predicts-greater-improvement-in-negative-symptoms-in-first-episode-schizophrenia
#28
JOURNAL ARTICLE
Xiaobing Sun, Ruiqing He, Yuan Xiao, Meihong Xiu, Maodi Sun, Fengchun Wu, Xiang Yang Zhang
Several studies have reported that baseline symptom severity in patients with schizophrenia (SCZ) is associated with the efficacy of antipsychotic medication. Overweight/obesity is common in SCZ and has also been reported to be correlated with therapeutic response to antipsychotics. This study aimed to evaluate whether baseline body mass index (BMI) and disease severity were associated with improvements in negative symptoms in patients with first-episode and medication-naïve (FEMN) SCZ. A total of 241 FEMN patients were recruited in this study and treated with oral risperidone over 3 months...
March 27, 2024: European Archives of Psychiatry and Clinical Neuroscience
https://read.qxmd.com/read/38523642/prediction-of-antipsychotics-efficacy-based-on-a-polygenic-risk-score-a-real-world-cohort-study
#29
JOURNAL ARTICLE
Marco De Pieri, Marco Ferrari, Giorgio Pistis, Franziska Gamma, Franca Marino, Armin Von Gunten, Philippe Conus, Marco Cosentino, Chin-Bin Eap
Background: Response to antipsychotics is subject to a wide interindividual variability, due to genetic and non-genetic factors. Several single nucleotide polymorphisms (SNPs) have been associated with response to antipsychotics in genome-wide association studies (GWAS). Polygenic risk scores (PRS) are a powerful tool to aggregate into a single measure the small effects of multiple risk alleles. Materials and methods: We studied the association between a PRS composed of SNPs associated with response to antipsychotics in GWAS studies (PRSresponse ) in a real-world sample of patients (N = 460) with different diagnoses (schizophrenia spectrum, bipolar, depressive, neurocognitive, substance use disorders and miscellaneous)...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38523268/medication-non-adherence-and-self-inflicted-violence-behaviors-among-185-800-patients-with-schizophrenia-in-the-community-a-12-year-cohort-study
#30
JOURNAL ARTICLE
Chuanlong Zuo, Xianmei Yang, Xiangrui Wu, Ruoxin Fan, Jun Liu, Hu Xiang, Yang Li, Xing Zhao, Xiang Liu, Yuanyuan Liu
BACKGROUND: Despite the importance of medication adherence in treatment effectiveness, little is known about the association between medication non-adherence and self-inflicted violence behaviors. We aimed to assess whether medication non-adherence increased the risk of self-inflicted violence behaviors among schizophrenics in communities (hypothesis 1) and whether the dose-response relationship existed (hypothesis 2). METHODS: This 12-year cohort study in western China recruited 292,667 community-dwelling schizophrenics...
March 25, 2024: BMC Medicine
https://read.qxmd.com/read/38516266/methylome-wide-and-meqtl-analysis-helps-to-distinguish-treatment-response-from-non-response-and-pathogenesis-markers-in-schizophrenia
#31
JOURNAL ARTICLE
Binithamol K Polakkattil, Neetha N Vellichirammal, Indu V Nair, Chandrasekharan M Nair, Moinak Banerjee
Schizophrenia is a complex condition with entwined genetic and epigenetic risk factors, posing a challenge to disentangle the intermixed pathological and therapeutic epigenetic signatures. To resolve this, we performed 850K methylome-wide and 700K genome-wide studies on the same set of schizophrenia patients by stratifying them into responders, non-responders, and drug-naïve patients. The key genes that signified the response were followed up using real-time gene expression studies to understand the effect of antipsychotics at the gene transcription level...
2024: Frontiers in Psychiatry
https://read.qxmd.com/read/38511167/the-altered-volume-of-striatum-a-neuroimaging-marker-of-treatment-in-first-episode-and-drug-na%C3%A3-ve-schizophrenia
#32
JOURNAL ARTICLE
Gao-Xia Wei, Haoran Shen, Li-Kun Ge, Bo Cao, Roja Manohar, Xiangyang Zhang
Although schizophrenia patients exhibit structural abnormalities in the striatum, it remains largely unknown for the role of the striatum subregions in the treatment response of antipsychotic drugs. The purpose of this study was to investigate the associations between the striatal subregions and improved clinical symptoms in first-episode drug-naïve (FEDN) schizophrenia. Forty-two FEDN schizophrenia patients and 29 healthy controls (HCs) were recruited. At baseline, the Positive and Negative Syndrome Scale (PANSS) was used to assess the clinical symptoms of patients, MRI scanner was used to obtain anatomical images of patients and HCs...
June 2024: Schizophrenia Research. Cognition
https://read.qxmd.com/read/38507639/labyrinthine-and-neuroscientific-impact-of-schizophrenia-in-the-criminal-justice-system
#33
JOURNAL ARTICLE
Prashant Kumar, Rana Navneet Roy, Shivakant Prajapati
Schizophrenia, a complex neuropsychiatric condition, manifests with severe neurobiological and psychosocial symptoms, including psychosis, cognitive dysfunction, and social withdrawal. Neuroscience links these symptoms to synaptic malfunctions and neurotransmitter dysregulation, leading to a profound disconnection from reality. The disorder significantly affects cognitive, affective, and behavioral functions, causing considerable neuropsychological distress and functional impairments. The interplay of schizophrenia with the criminal justice system is complex, often exacerbating psychiatric stigma and introducing challenging neuroethical dilemmas...
March 18, 2024: International Tinnitus Journal
https://read.qxmd.com/read/38506802/baseline-antipsychotic-dose-and-transition-to-psychosis-in-individuals-at-clinical-high-risk-a-systematic-review-and-meta-analysis
#34
JOURNAL ARTICLE
Andrea Raballo, Michele Poletti, Antonio Preti
IMPORTANCE: Emerging meta-analytical evidence indicates that baseline exposure to antipsychotics is associated with an increased risk of transitioning to psychosis in individuals at clinical high-risk for psychosis (CHR-P) and that such effect is not a result of pretest risk enrichment. However, to maximize its translational utility for prognostic stratification in clinical practice, testing for the potential presence of a dose-response association is crucial. OBJECTIVE: To test whether the negative prognostic effect of baseline antipsychotic exposure in individuals at CHR-P follows a dose-effect pattern, as indicated by mean chlorpromazine equivalent doses (CPZ-ED)...
March 20, 2024: JAMA Psychiatry
https://read.qxmd.com/read/38495905/corrigendum-the-effect-of-antipsychotics-on-glutamate-levels-in-the-anterior-cingulate-cortex-and-clinical-response-a-1-h-mrs-study-in-first-episode-psychosis-patients
#35
Uzma Zahid, Robert A McCutcheon, Faith Borgan, Sameer Jauhar, Fiona Pepper, Matthew M Nour, Maria Rogdaki, Martin Osugo, Graham K Murray, Pamela Hathway, Robin M Murray, Alice Egerton, Oliver D Howes
[This corrects the article DOI: 10.3389/fpsyt.2022.967941.].
2024: Frontiers in Psychiatry
https://read.qxmd.com/read/38494791/a-proposal-for-reducing-maximum-target-doses-of-drugs-for-psychosis-reviewing-dose-response-literature
#36
REVIEW
James R O'Neill, Adam Jameson, Samantha L McLean, Michael Dixon, Alastair G Cardno, Christopher Lawrence
BACKGROUND: Presently, there is limited guidance on the maximal dosing of psychosis drugs that is based on effectiveness rather than safety or toxicity. Current maximum dosing recommendations may far exceed the necessary degree of dopamine D2 receptor blockade required to treat psychosis. This may lead to excess harm through cognitive impairment and side effects. AIMS: This analysis aimed to establish guidance for prescribers by optimally dosing drugs for psychosis based on efficacy and benefit...
March 17, 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38494658/proportion-of-antipsychotics-with-cyp2d6-pharmacogenetic-pgx-associations-prescribed-in-an-early-intervention-in-psychosis-eip-cohort-a-cross-sectional-study
#37
JOURNAL ARTICLE
Adam Jameson, Muhammad Faisal, Beth Fylan, Greg C Bristow, Jaspreet Sohal, Caroline Dalton, Gurdeep S Sagoo, Alastair G Cardno, Samantha L McLean
BACKGROUND: Prescribing drugs for psychosis (antipsychotics) is challenging due to high rates of poor treatment outcomes, which are in part explained by an individual's genetics. Pharmacogenomic (PGx) testing can help clinicians tailor the choice or dose of psychosis drugs to an individual's genetics, particularly psychosis drugs with known variable response due to CYP2D6 gene variants ('CYP2D6-PGx antipsychotics'). AIMS: This study aims to investigate differences between demographic groups prescribed 'CYP2D6-PGx antipsychotics' and estimate the proportion of patients eligible for PGx testing based on current pharmacogenomics guidance...
March 17, 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38493023/response-rates-to-sequential-trials-of-antipsychotic-medications-according-to-algorithms-or-treatment-guidelines-in-psychotic-disorders-a-systematic-review-and-meta-analysis
#38
JOURNAL ARTICLE
Brian O'Donoghue, Francesco Piacenza, Helena Plapp, Dan Siskind, John Lyne
BACKGROUND: There is a relative lack of research evaluating the outcomes when treatment guidelines or algorithms for psychotic disorders are followed. This systematic review and meta-analysis determined the response rates to antipsychotic medications at different stages of these algorithms and whether these response rates differ in first episode cohorts. METHODS: Data sources: A systematic search strategy was conducted across four databases PubMed, EMBASE, PsycINFO (Ovid) and CINAHL...
March 16, 2024: Schizophrenia Research
https://read.qxmd.com/read/38492329/identification-and-treatment-of-individuals-with-childhood-onset-and-early-onset-schizophrenia
#39
REVIEW
Christoph U Correll, Celso Arango, Birgitte Fagerlund, Silvana Galderisi, Martien J Kas, Stefan Leucht
Approximately 8 % of patients with schizophrenia are diagnosed before age 18, and 18 % experience their first symptoms before age 18. This narrative review explores the management of patients with early-onset schizophrenia (EOS) and childhood-onset schizophrenia (COS) from diagnosis to their transition to adult care settings. Early diagnosis of schizophrenia in children and adolescents is essential for improving outcomes, but delays are common due to overlapping of symptoms with developmental phenomena and other psychiatric conditions, including substance use, and lack of clinicians' awareness...
March 15, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/38488388/effects-of-prenatal-exposure-to-second-generation-antipsychotics-on-development-and-behavior-among-preschool-aged-children-preliminary-results-from-the-national-pregnancy-registry-for-psychiatric-medications
#40
JOURNAL ARTICLE
Carol Swetlik, Lee S Cohen, Lauren A Kobylski, Ellen T Sojka, Parker C Killenberg, Marlene P Freeman, Adele C Viguera
Objective: Data are lacking on the neurodevelopmental outcomes of children prenatally exposed to second-generation antipsychotics (SGAs). The objective of this study is to examine neurodevelopmental outcomes of children exposed in utero to SGAs compared to those unexposed in a cohort of mothers with psychiatric morbidity. Methods: We conducted a cross-sectional assessment of preschool-aged children whose mothers were enrolled in the National Pregnancy Registry for Psychiatric Medications. Two validated, parent-report developmental and behavioral screening assessments, the Ages and Stages Questionnaire, Third Edition (ASQ-3) and the Preschool Child Behavior Checklist for Ages 1½-5 (CBCL/1½-5), respectively, were delivered electronically to eligible participants...
March 13, 2024: Journal of Clinical Psychiatry
keyword
keyword
50550
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.